In a deal that could be worth more than US$200 M, Avanir Pharmaceuticals has licensed global rights to Concert Pharmaceuticals’ multiple deuterium-modified dextromethorphan (d-DM) products for the potential treatment of neurological and psychiatric disorders. Avanir’s sole marketed product is Nuedexta® (dextromethorphan plus quinidine sulphate), which was approved by the US FDA in 2010 for pseudobulbar affect.